FDA Long-Term Globalization Strategy Under Development
"Third-party inspection programs need to be a bigger part of the discussion so that we don't have to do the work all ourselves," said John Taylor, FDA acting principal deputy commissioner. "We simply cannot do it alone."
More from Archive
More from Pink Sheet
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.